Novo Nordisk GLP-1 Lawsuits: What Patients Need to Know

Novo Nordisk, the pharmaceutical company behind semaglutide (marketed as Ozempic and Wegovy), faces a growing number of lawsuits related to its GLP-1 medications. These legal actions span side effect claims, pricing practices, and patent strategies. For the millions of patients currently taking semaglutide, understanding these lawsuits is important for informed decision-making.

Side Effect Lawsuits

The largest category of lawsuits against Novo Nordisk alleges that the company failed to adequately warn patients and prescribers about serious gastrointestinal side effects. Plaintiffs claim they developed severe gastroparesis (stomach paralysis), intestinal obstruction, pancreatitis, or gallbladder disease after taking Ozempic or Wegovy, and that these risks were not sufficiently communicated in the medication's labeling.

In August 2023, a multidistrict litigation (MDL) was established in the Eastern District of Pennsylvania to consolidate hundreds of individual lawsuits. The MDL process allows for coordinated discovery and potential bellwether trials that could set precedent for future cases. As of early 2026, the litigation continues through the discovery phase.

Pricing-Related Legal Actions

Novo Nordisk faces increasing legal and legislative scrutiny over the pricing of its GLP-1 medications. Ozempic and Wegovy are priced at over $1,000 per month in the United States while available for a fraction of that cost in other countries. Congressional investigations have examined whether the company engaged in anticompetitive pricing practices. Some state attorneys general have initiated investigations into GLP-1 pricing practices by multiple manufacturers.

Patent Strategy Challenges

Novo Nordisk holds multiple patents on semaglutide, and legal challenges to these patents could accelerate the availability of generic versions. Patent challenges typically involve allegations of "evergreening" (filing incremental patents to extend market exclusivity), overly broad patent claims, and anticompetitive agreements with potential generic manufacturers. The outcome of these patent challenges directly affects when more affordable generic semaglutide might become available.

What This Means for Current Patients

If you are currently taking semaglutide, these lawsuits do not necessarily mean you should stop your medication. The lawsuits allege inadequate warnings, not that the medication is inherently unsafe for all patients. Millions of people use semaglutide safely and effectively. The key is working with a knowledgeable provider who understands the risk profile, monitors for complications, and adjusts treatment as needed.

If you have experienced serious side effects, document everything: medical records, timelines, communications with your provider, and any impact on your daily life. Consult a pharmaceutical litigation attorney for a confidential case evaluation.

Implications for Compounded Semaglutide

These lawsuits primarily target Novo Nordisk's conduct, not the semaglutide molecule itself. Compounded semaglutide from providers like Trimi uses the same active ingredient but is produced by independent compounding pharmacies. The legal issues with the brand-name manufacturer do not change the safety or efficacy of the semaglutide molecule when properly compounded and prescribed.

Staying Informed

GLP-1 litigation is evolving rapidly. Key developments to watch include the outcome of bellwether trials in the MDL, FDA label updates that may result from legal pressure, Congressional action on GLP-1 pricing, and patent challenge outcomes. Reliable sources for updates include the FDA's MedWatch system, legal news outlets, and your healthcare provider.

The Bottom Line

Lawsuits against Novo Nordisk reflect growing scrutiny of pharmaceutical industry practices around GLP-1 medications. For patients, the takeaway is to stay informed, work with attentive providers, report any serious side effects, and make medication decisions based on your individual risk-benefit profile rather than headlines. If affordability is a concern, compounded alternatives provide the same active medication at a fraction of the cost.